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Abstract
Colorectal cancer is one of the most common cancer types and still a major public health
problem. Approximately a half of the patients develop metastasis during the course of
disease. Prognosis of metastatic colorectal cancer (mCRC) is poor with best suppor‐
tive care alone (median survival: 6 months). Fortunately, combination chemotherapy
has significantly improved survival up to 17–22 months. Cetuximab and panitumu‐
mab, the two monoclonal antibodies (mAbs) against epidermal growth factor receptor
(EGFR), provide significant clinical benefit in only RAS wild (WT) mCRC. Major side
effects are skin toxicity, infusion reactions, fatigue, and electrolyte imbalances. When
these mAbs are combined with chemotherapy, overall survival could be as long as 24
months. However, RAS WT status does not ensure response to anti-EGFR mAbs. In
addition, RAS WT patients consequently develop resistance to these agents after an
initial  responsive  period.  Therefore,  understanding  the  primary  and  secondary
resistance mechanisms apart from RAS status is very important to improve outcomes
of  mCRC  patients.  Oncogenic  activation  of  EGFR  downstream  signaling  effectors
(KRAS, BRAF, PTEN, and PIK3CA) appears to be the main components of resistance.
In future, a comprehensive biomarker analysis will probably help to identify the mCRC
patients who will truly benefit from anti-EGFR mAbs.
Keywords: cetuximab, metastatic colorectal cancer, panitumumab, RAS, survival
1. Introduction
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in both genders (second
in females and third in males) [1]; and it is also the third common cause of cancer-related death
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in both genders [2, 3]. Although the mortality rate of CRC has been decreasing in Western
countries, its incidence has been increasing worldwide [1].
CRC can spread by lymphatic, hematogenous and transperitoneal dissemination. The most
common metastatic sites are the regional lymph nodes, liver, lungs, and peritoneum. Approx‐
imately 50–60% of patients with CRC develop metastasis, and local recurrence is included in
15% of the patients who have first relapse [4].
Survival of metastatic colorectal cancer (mCRC) is approximately 5–6 months with best
supportive care (BSC) alone, and chemotherapeutic agents have been shown to provide
significant survival benefit. Fluoropyrimidines have been the mainstay of the systemic
treatment of mCRC for several years. Median survival of patients with mCRC increased up to
12–14 months and 17–22 months with fluoropyrimidines alone and its combinations with
irinotecan and/or oxaliplatin, respectively [5–7]. Also, addition of target-directed cancer drugs,
such as monoclonal antibodies (mAbs) against VEGF (e.g., bevacizumab, aflibercept) and
EGFR (e.g., cetuximab and panitumumab), have remarkably improved the outcomes of mCRC
[8–13]. Unfortunately, targeted therapies, including anti-EGFR drugs, are active only in a
fraction of patients and most of them subsequently become resistant to the treatment. There‐
fore, identification of the genetic alterations associated with the clinical response and resistance
to anti-EGFR mAbs is important to improve outcomes of patients with mCRC.
2. Epidermal growth factor receptor and KRAS mutation
Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor that
presents on the surface of normal epithelium. It is over-expressed in up to 80% of colorectal
tumors [14, 15] and mediates cell differentiation, proliferation, migration, angiogenesis and
apoptosis [16].
The EGFR signaling acts through at least two parallel intracellular pathways: mitogen-
activated protein kinases (MAPK) and phosphor-inositol kinases (PI3K). MAPK form the
major cell proliferation signaling pathways from the cell surface to the nucleus through a series
of genes, including RAS, RAF, and MEK. Various signals, such as EGF, amphiregulin,
amphiregulin, and heparin-binding EGF, could stimulate EGFR. After dimerization and
phosphorylation of the stimulated EGFR, RAS is activated [17]. RAS activation, which starts
the PI3K and RAF cascades, is the central distributor of the signal. Activation of PI3K/AKT
pathway inhibits apoptosis, whereas RAF activation stimulates cellular proliferation. Hence,
mutations in the KRAS gene may result in an independent activation of the downstream
signaling of tumor growth [17]. Prospective randomized trials elucidated that presence of
mutation in KRAS gene leads to non-response to anti-EGFR–based treatment in mCRC [8–12,
18–20].
Incidence of KRAS mutations is approximately 28.7% in all human cancers, thus it is consid‐
ered one of the causal cancer genes [17]. RAS mutations occur in the early phases of cancer
development and are preserved during tumor progression. KRAS mutation rate in CRC is 36%
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and most common point mutations are located in codons 12 (80%) and 13 (15%) of exon 2,
while codon 61, 117, and 146 mutations are less common [17, 21]. Unusual KRAS mutations
affecting more than one codon and insertions are rare. The discordance of KRAS status between
primary tumor and synchronous metastasis in the same patient tends to be low (ranging from
0 to 31%) [22]. In addition, KRAS status is not different between CRC biopsies before and after
neoadjuvant therapy [23], or the biopsy and resection specimens of CRC [21, 24]. Because the
data are limited, routine rebiopsy of metastases for RAS mutation analysis in recurrent disease
is not recommended currently. In contrast, RAS mutations vary significantly between syn‐
chronous primary CRC lesions, therefore the mutation status of the metastasis is unpredictable
[21].
3. Anti-EGFR mAbs in mCRC
Cetuximab (Erbitux) and panitumumab (Vectibix) are the two anti-EGFR mAbs active for the
treatment of mCRC. Both are effective only in the wild type (WT) RAS (NRAS and KRAS)
tumors (approximately 40% of all mCRCs) [8–12, 18–20]. Therefore, it is well established that
KRAS and NRAS mutation status (exons 2, 3, and 4) should be known before initiating anti-
EGFR based treatment for mCRC [25].
3.1. Mechanism of action
Cetuximab and panitumumab keep EGFR in an inactive state by binding to the extracellular
ligand-binding site of EGFR when the ligand is unbound (acting as competitive antagonists).
Consequently, intracellular signaling pathways of EGFR (RAS/RAF/MAPK and PI3K/PTEN/
AKT) related to cell proliferation, invasion, and survival are inhibited [26][Figure 1]. Both
cetuximab, an IgG1 type chimeric monoclonal antibody, and panitumumab, an IgG2 type fully
human monoclonal antibody, induce apoptosis by inhibiting EGFR. Also, these molecules,
especially cetuximab, activate antibody-dependent cellular cytotoxicity, inhibit metastasis and
angiogenesis by blocking ligand-induced phosphorylation of EGFR on endothelial cells [16,
27, 28].
3.2. Predictive markers for response
The identification of patients with mCRC who are most likely to respond to the anti-EGFR
mAbs is an important clinical question. Although there are no accepted predictive markers of
response to bevacizumab or to chemotherapeutics, there are some analyses to select individ‐
uals who might benefit from anti-EGFR mAbs.
3.3. RAS mutations
Activating KRAS mutations cause constitutive activation of the RAS-RAF-ERK pathway, even
in the absence of EGFR ligands. Consequently, tumor becomes resistant to anti-EGFR therapy
[16, 17, 21, 29]. Prospective randomized studies showed that KRAS mutations are negative
predictors of the response to anti-EGFR–based treatment [8–12, 18–20]. Thus, panitumumab
and cetuximab are approved only for patients with WT KRAS tumors.
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All KRAS mutations may not be similar for prediction of anti-EGFR therapy [30–33]. Although
some retrospective studies suggest that patients with KRAS p.G13D mutation benefit more
from cetuximab than those with KRAS codon 12 mutations [32], this benefit could not be
confirmed in a prospective trial [33]. Therefore, data are not enough to change the clinical
practice or to draw any firm conclusions about the effectiveness of anti-EGFR mAbs in mCRC
with KRAS p.G13D mutation.
Almost 60% of CRC patients with WT KRAS mutation also have poor response to anti-EGFR–
based treatment [34], suggesting the possibility of other molecular determinants of response.
Heterogeneity of neoplastic cells that harbor specific RAS mutations within a single tumor
may also influence response to EGFR-targeted agents [35]. Lower frequency mutations in
KRAS apart from exon 2 or in NRAS may also cause resistance to anti-EGFR therapies [18, 36–
41]. NRAS mutations in mCRC are less common than KRAS mutations (approximately 5%)
and develop most often in codons 61, 12, and 13 [21]. The PRIME trial, in which patients with
mCRC were randomly assigned to first-line FOLFOX with or without panitumumab, revealed
that 17% of the patients with KRAS exon 2 WT tumors had other mutations in KRAS exons 3
and 4 and in NRAS exons 2, 3, and 4 [38]. These additional mutations were also associated
Figure 1. Epidermal growth factor receptor pathway as a therapeutic target for metastatic colorectal cancer.
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with unresponsiveness to panitumumab, and poorer progression-free and overall survival in
the panitumumab arm. Currently, testing for all RAS mutations (KRAS and NRAS exons 2, 3,
and 4 ) rather than just those in KRAS exon 2 is the preferred approach to select appropriate
patients with mCRC for anti-EGFR mAbs, since anti-EGFR mAbs are neither beneficial nor
recommended for mCRC with any KRAS or NRAS mutations [42].
3.4. Other biomarkers
As mentioned before, WT RAS status does not ensure a response to EGFR-targeted therapies.
Interestingly, the expression of the EGFR protein has not been strongly associated with clinical
response to cetuximab in mCRC [43]. Majority of patients with EGFR-positive mCRC do not
respond to anti-EGFR therapies [44, 45], while objective response is possible with EGFR-
negative tumors [46–48]. Therefore, selection of patients for anti-EGFR mAbs based upon
EGFR expression is not recommended. Likewise, EGFR mutations are rare in mCRC, and
somatic mutations in the EGFR tyrosine kinase domain are not associated with cetuximab
sensitivity [49]. However, it has been reported that over-expression of genes encoding
amphiregulin and epiregulin, the two EGFR ligands, is strongly associated with better
response to cetuximab in patients with mCRC [43].
Results of studies about association between EGFR copy number and response to anti-EGFR
therapy are conflicting [44, 50–53]. Thus, EGFR amplification test to select patients for therapy
is not standard in clinical practice.
BRAF mutations, which are mutually exclusive with KRAS mutations, are found in about 5 to
10% of mCRCs. BRAF mutations are associated with poor prognosis [54] and resistance to anti-
EGFR agents in the second-line setting and beyond [50, 55]. Although randomized trials
confirm the prognostic value of BRAF mutations, it does not have predictive role for anti-EGFR
agents in first-line setting [56, 57]. Currently, BRAF mutation analysis should not be used for
the selection of patients with WT RAS mCRC for anti-EGFR therapy.
Mutations of other genes, including phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
subunit alpha (PIK3CA) [58], p53 [59], PTEN [50] and genes involved in the insulin-like growth
factor 1 (IGF1) signaling pathway [60, 61], or polymorphisms in EGF [62] may also have an
impact on response to anti-EGFR mAbs. However, these biomarkers are not mature enough
to be incorporated into clinical practice.
4. Clinical efficacy of anti-EGFR mAbs in mCRC
4.1. Cetuximab
4.1.1. Cetuximab monotherapy
In a randomized phase III trial, cetuximab monotherapy and BSC were compared in patients
with mCRC who had failed or were intolerant of all standard therapies (n = 572) [63]. Partial
response rate was 8% with cetuximab and overall survival (OS) was significantly improved
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with cetuximab (6.1 vs. 4.6 months). Subgroup analysis revealed that only patients with KRAS
WT tumor provided survival benefit from cetuximab [19, 64]. Among patients with mutated
KRAS, survival was similar in cetuximab and BSC arms.
4.1.2. Cetuximab combinations
4.1.2.1. Combination with irinotecan
A phase II study compared efficacy of cetuximab plus irinotecan and single agent irinotecan
in 138 patients with irinotecan-refractory mCRC [65]. Partial response rate and time to tumor
progression (TTP) were 15% and 6.5 months, respectively.
The BOND trial, a larger randomized phase II trial, compared irinotecan plus cetuximab versus
cetuximab alone in 329 patients with irinotecan-refractory mCRC [9]. Combination therapy
was significantly better than single agent cetuximab in terms of response rate (22.9% vs. 10.8%)
and TTP (4.1 vs. 1.5 months); however, median survival was similar (8.6 vs. 6.9 months). In
addition, benefit of adding cetuximab to irinotecan in patients with oxaliplatin-refractory
mCRC has been reported in the EPIC trial [66]. Both objective response rates (16 vs. 4%) and
PFS (4 vs. 2.6 months) were significantly higher with irinotecan plus cetuximab compared with
single agent irinotecan. However, OS was similar (10.7 vs. 10 months), probably because of
cross-over.
Study Year  Popula
tion
Patient
number
Regimen Median
PFS
(month)
p* Median
OS (month)
p* Response
rate (%)
p*
CRYSTAL57 2009  All 599 FOLFIRI 8 0.048 18.6 0.31 38.7 0.0038
599 FOLFIRI + 
Cetuximab
8.9 19.9 46.9
KRAS
WT
subgroup
350 FOLFIRI 8.4 0.0012 20 0.0093 39.7 <0.001
316 FOLFIRI + 
Cetuximab
9.9 23.5 57.3
KRAS
MT
subgroup
183 FOLFIRI 7.7 0.26 16.7 0.75 36.1 0.35
214 FOLFIRI + 
Cetuximab
7.4 16.2 31.3
OPUS18 2009  All 168 FOLFOX4 7.2 0.62 18 0.91 36 0.064
169 FOLFOX4 + 
Cetuximab
7.2 18.3 46
KRAS
WT
subgroup
97 FOLFOX4 7.2 0.0064 18.5 0.39 34 0.0027
82 FOLFOX4 + 
Cetuximab
8.3 22.8 57
KRAS 59 FOLFOX4 8.6 0.0153 17.5 0.2 53 0.029
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Study Year  Popula
tion
Patient
number
Regimen Median
PFS
(month)
p* Median
OS (month)
p* Response
rate (%)
p*
MT
subgroup
77 FOLFOX4 + 
Cetuximab
5.5 13.4 34
COIN67 2011 KRAS
WT
group
367 FOLFOX/
XELOX
8.6 0.60 17.9 0.68 57 0.049
362 FOLFOX/
XELOX + 
Cetuximab
8.6 17 64
KRAS
WT
group
127 FOLFOX 9.2 0.056 – – – –
117 FOLFOX + 
Cetuximab
9.0 – –
KRAS
WT
group
240 XELOX 8.0 0.56 – – – –
245 XELOX + 
Cetuximab
8.4 – –
KRAS
MT
group
268 FOLFOX/
XELOX
- - 14.8 0.80 - -
297 FOLFOX/
XELOX + 
Cetuximab
– 13.6 –
NORDIC-
VII68
2012 All 185 Nordic FLOX
(control
group)
7.9 – 20.4 – 41 –
194 FLOX + 
Cetuximab
8.3 0.31 19.7 0.67 49 0.15
187 intermittent
FLOX + 
Cetuximab
7.3 N/A 20.3 0.79 47 N/A
KRAS
WT
subgroup
97 Nordic FLOX
(control
group)
8.7 – 22 – 47 –
97 FLOX + 
Cetuximab
7.9 0.66 20.1 0.48 46 0.89
109 intermittent
FLOX + 
Cetuximab
7.5 N/A 21.4 0.66 51 N/A
KRAS
MT
58 Nordic FLOX
(control
7.8 – 20.4 – 40 –
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Study Year  Popula
tion
Patient
number
Regimen Median
PFS
(month)
p* Median
OS (month)
p* Response
rate (%)
p*
subgroup group)
72 FLOX + 
Cetuximab
9.2 0.07 21.1 0.89 49 0.31
65 intermittent
FLOX + 
Cetuximab
7.2 N/A 20.5 0.84 42 N/A
CALGB
/SWOG69
80405
(study is
ongoing)
2014 KRAS
WT
group
578 FOLFIRI or
mFOLFOX6 + 
Cetuximab
10.45 N/A 29.93 0.34 – –
559 FOLFIRI or
mFOLFOX6 + 
Bevacizumab
10.84 29.04 –
*95% confidence interval.
PFS, progression-free survival; OS, overall survival; All, all patients group; WT, wild type; MT, mutant type; N/A, not
available; KRAS, KRAS exon 2, codons 12 and 13; FOLFIRI, irinotecan, fluorouracil, and leucovorin; FOLFOX,
fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine and oxaliplatin; FLOX, fluorouracil, leucovorin, and
oxaliplatin.
Table 1. Clinical trials of cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer.
The CRYSTAL trial enrolled 1200 patients with mCRC and investigated the role of adding
cetuximab to FOLFIRI as first-line therapy [8]. Response rate (47 vs. 39%) and median PFS (8.9
vs. 8 months), the primary end point of the study, were significantly better with FOLFIRI plus
cetuximab compared with FOLFIRI alone, while OS was not significantly different between
groups. An updated analysis of the CRYSTAL trial also demonstrated that adding cetuximab
to FOLFIRI significantly improves OS (23.5 vs. 20 months), PFS (9.9 vs. 8.4 months), and
response rate (57.3% vs. 39.7%) in patients with WT KRAS tumor. Perhaps more importantly,
the rate of surgery for metastasis (7.9 vs. 4.6%, p = 0.06) and the rate of R0 resection (5.1 vs. 2%,
p = 0.02) were both higher in patients with KRAS WT tumors who received cetuximab plus
FOLFIRI compared with FOLFIRI alone [57]. Adverse effects that were more frequent with
cetuximab were grade 3 or 4 diarrhea, skin toxicity, and infusion reactions. Based in large part
on these data, cetuximab was approved for use in combination with FOLFIRI for first-line
treatment of patients with KRAS WT mCRC [Table 1].
4.1.2.2. Combination with oxaliplatin
Randomized trials revealed conflicting results about benefits of adding cetuximab to oxali‐
platin-based regimens. Three trials have evaluated the addition of cetuximab to oxaliplatin-
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based chemotherapy (FOLFOX/CAPOX) in first-line treatment of KRAS WT mCRC [18, 67,
68]. In randomized multicenter phase II OPUS study, FOLFOX4 plus cetuximab was compared
with FOLFOX4 alone. Cetuximab provided significantly better response rate (61 vs. 37 %) and
PFS (7.7 vs. 7.2 months) among patients with KRAS exon 2 WT tumors. However, median OS
did not improve with addition of cetuximab (22.8 vs. 18.5) [18].
In randomized phase III MRC COIN study, adding cetuximab to oxaliplatin-based chemo‐
therapy in patients with KRAS exon 2 WT mCRC increased response rate (64 vs. 57%) with no
benefit in PFS (8.6 months in both groups) or OS (17.9 vs. 17) [67]. Likewise, another phase III
study (NORDIC-VII) showed no survival benefit with the addition of cetuximab to FLOX
regimen even in the KRAS WT group [68].
On the other hand, recently published randomized phase III CALGB/SWOG 80405 trial, in
which 73% of the enrolled patients received FOLFOX as chemotherapy backbone, demon‐
strated that FOLFOX plus cetuximab can be effective as first-line treatment of patients with
KRAS WT mCRC [69].
Converting initially unresectable isolated liver metastases to resectable status is another
important issue for patients with mCRC, as R0 resection of isolated metastasis provide
significant survival benefit. In the OPUS trial, addition of cetuximab to FOLFOX4 significantly
increased ability for R0 resection of isolated liver metastasis [18]. In addition, the randomized
phase II CELIM trial demonstrated that adding cetuximab to either irinotecan or oxaliplatin-
based chemotherapy has similar efficacy in patients with initially unresectable liver metastases
[70]. However, the efficacy of cetuximab-oxaliplatin combination for downstaging patients
with isolated CRC liver metastases is unsettled. Recently, the randomized EPOC trial demon‐
strated that adding cetuximab to FOLFOX in patients with KRAS WT and potentially resectable
isolated liver metastases was associated with worse PFS (14.8 vs. 24.2 months) [71]. Therefore,
FOLFOX plus cetuximab should be used with caution in perioperative metastatic setting.
4.2. Panitumumab
4.2.1. Panitumumab monotherapy
In a multicenter trial (n = 463) adding panitumumab to BSC provided a 10% objective response
rate in patients with mCRC refractory to standard treatment options [12, 72]. However, there
was no significant PFS benefit, probably because of cross-over. Re-analysis according to KRAS
status demonstrated that benefit of panitumumab monotherapy was restricted to KRAS WT
tumors. Partial response rates in patients with KRAS WT and mutant tumors were 17% and
0%, respectively [73]. Although efficacy of panitumumab is similar to cetuximab monotherapy
[63, 74], there is no data supporting to switch the anti-EGFR mAbs cetuximab and panitumu‐
mab after one of them fails.
4.2.2. Panitumumab combinations
There are increasing data supporting the efficacy of panitumumab in combination with
oxaliplatin- or irinotecan-based regimens in patients with WT RAS tumors [10, 75–80].
Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer
http://dx.doi.org/10.5772/62304
353
4.2.2.1. Combination with irinotecan
The efficacy of first-line FOLFIRI-panitumumab combination in mCRC was evaluated in a
single-arm phase II study. This regimen was well tolerated and response rates were 48% and
29% in the KRAS WT and mutant subsets, respectively [81]. Except this study, data regarding
to FOLFIRI-panitumumab combination at first-line setting is mainly based on extrapolation
from data in the second-line treatment. As an example, in a randomized phase III study (Study
181) the combination of panitumumab and FOLFIRI provide significant PFS benefit (5.9 vs. 3.9
months), but there was no difference in OS in patients with WT KRAS mCRC [11].
4.2.2.2. Combination with oxaliplatin
The phase III PRIME study compared panitumumab plus FOLFOX and FOLFOX alone as first-
line treatment of patients with pan-RAS WT mCRC. Addition of panitumumab to FOLFOX
significantly improved both PFS (10.1 vs. 9.2 months) and OS (23.8 vs. 19.4 months) [38].
Importantly, addition of panitumumab deteriorated PFS (7.3 vs. 8.9 months) in patients with
KRAS mutation, consistent with other trials testing the addition of panitumumab or cetuximab
to oxaliplatin-based chemotherapy [Table 2]. In addition, 17% of those with non-mutated
KRAS exon 2 had other RAS mutations. These mutations were associated with worse PFS and
OS with adding panitumumab to FOLFOX, similar to KRAS exon 2 mutations [38].
Study Year Population Patient
number
Regimen Median
PFS
(month)
p* Median
OS
(month)
p* Response rate (%) p*
PRIME10 2010 KRAS WT
group
331 FOLFOX4 8.0 0.02 19.7 0.072 48 0.068
325 FOLFOX4 + 
Panitumumab
9.6 23.9 55
KRAS MT
group
219 FOLFOX4 8.8 0.02 19.3 0.068 40 –
221 FOLFOX4 + 
Panitumumab
7.3 15.5 40
*95% Confidence interval.
PFS, progression-free survival; OS, overall survival; All, all patients group; WT, wild type; MT, mutant type; N/A, not
available; KRAS, KRAS exon 2, codons 12 and 13; FOLFOX, fluorouracil, leucovorin, and oxaliplatin.
Table 2. Selected phase III trial of panitumumab plus chemotherapy as first-line treatment for metastatic colorectal
cancer.
4.2.3. Cetuximab versus panitumumab
Data are limited about head-to-head comparison of panitumumab and cetuximab in mCRC.
The ASPECCT trial, a randomized non-inferiority phase III study, showed that median OS was
similar in patients with chemorefractory KRAS exon 2 WT mCRC who were treated with
panitumumab (6 mg/kg once every 2 weeks) alone and with cetuximab (initial dose 400
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mg/m2, 250 mg/m2 once a week thereafter) alone [82]. In addition, the incidence of any grade
and grade 3–4 adverse events was similar in both treatment groups. However, the incidence
of grade 3–4 infusion reactions was lower and grade 3–4 hypomagnesemia is higher with
panitumumab compared with cetuximab [83]. Currently, there are no data supporting to use
panitumumab or cetuximab beyond progression under an anti-EGFR mAb or to switch to
cetuximab or panitumumab after one of them fails.
4.2.4. Bevacizumab versus cetuximab or panitumumab in combination with chemotherapy
Three trials have compared the benefits of anti-EGFR mAbs and anti-VEGF bevacizumab in
combination with chemotherapy in RAS WT mCRC and the results are mixed.
In the FIRE-3 trial, patients with mCRC were randomly assigned to FOLFIRI with either
bevacizumab or cetuximab as first-line treatment [20, 39]. Patients who had pan-RAS WT
tumor had significantly better objective response rates (76 vs. 65 %) and OS (33.1 vs. 25.9
months) with cetuximab compared with bevacizumab, while PFS were not different between
groups (10.5 vs. 10.4 months). Grade 1–2 emesis, hypertension, abscesses, and bleeding were
more frequent with bevacizumab, and grade 1–2 hypocalcemia, and grade 3–4 skin toxicity,
infusion reactions, and hypomagnesemia were more common with cetuximab. The reason for
longer OS, in the absence of a better PFS, is unclear. Patients were on protocol-specified therapy
for 5 months and the survival curves did not diverge until 24 months, suggesting that
subsequent therapies beyond first-line treatment, which were not detailed in the report, may
be important.
In the phase II PEAK trial, FOLFOX plus panitumumab was compared with FOLFOX plus
bevacizumab as first-line treatment of mCRC [84]. For patients with KRAS exon 2 WT tumors,
OS was significantly better (34 vs. 24 months) with panitumumab, while PFS was similar. When
only pan-RAS WT patients were included, PFS was significantly better with panitumumab (13
vs. 9.5 months) but the statistical significance of the difference in OS disappeared, although
potentially clinically meaningful (41 vs. 29 months, p = 0.06).
The recently published phase III CALGB/SWOG 80405 trial, in which patients with KRAS exon
2 WT mCRC were randomly assigned to cetuximab or bevacizumab plus chemotherapy
(FOLFOX or FOLFIRI) as first-line treatment, demonstrated that both OS (29.9 vs. 29 months)
and PFS (10.4 vs. 10.8 months) were similar [69]. FOLFOX was chosen in more than 70% of
patients in this study. When only pan-RAS WT patients were analyzed, objective response
rates were significantly higher with cetuximab (69 vs. 54 %), while OS (32 vs. 31.2 months) and
PFS (11.4 vs. 11.3 months) were similar in both arms [85]. In conclusion, whether it is preferable
to add an anti-EGFR mAb rather than bevacizumab to first-line chemotherapy in RAS WT
mCRC is unclear [Table 1]. Preferring an anti-EGFR mAb rather than bevacizumab appears
to be reasonable for patients with symptomatic tumors, in which response rate is a clinically
more important purpose or if the use of bevacizumab is contraindicated. In addition, anti-
EGFR mAbs appear to be not superior to bevacizumab in second-line therapy and beyond. In
a phase II study (SPIRITT trial), patients with KRAS WT mCRC were randomized to FOLFIRI
plus bevacizumab or FOLFIRI plus panitumumab as second-line therapy after failure of first-
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line bevacizumab plus oxaliplatin-based chemotherapy. PFS was similar in both group (9.2 vs.
7.7 months) [86].
4.2.5. Simultaneous use of cetuximab/panitumumab and bevacizumab
Two trials evaluated the addition of an anti-EGFR mAb to chemotherapy plus bevacizumab
as first-line treatment of mCRC. The PACCE trial compared the efficacy of adding panitumu‐
mab to first-line oxaliplatin- (n = 823) or irinotecan (n = 230)-based chemotherapy plus
bevacizumab [87]. The panitumumab/oxaliplatin group had significantly worse PFS and OS.
Similar detrimental effect of dual antibody therapy was also observed in the CAIRO2 trial,
which compared first-line XELOX plus bevacizumab with or without cetuximab [88]. PFS was
significantly worse with the addition of cetuximab even in patients with KRAS WT tumors.
These results suggest that using bevacizumab and panitumumab/cetuximab is not appropri‐
ate, at least in the first-line setting.
5. Toxicity profile of the anti-EGFR mAbs
The most common adverse effects associated with cetuximab and panitumumab are fatigue,
acneiform rash, nausea, electrolyte imbalances, and infusion reactions [89–91].
5.1. Skin toxicity
Anti-EGFR therapies are associated with a variety of cutaneous side effects. Acneiform rash is
the most common skin toxicity and occurs in up to two-thirds of patients. Interestingly, severity
of rash correlates with better response rates [89, 92, 93]. Moreover, the EVEREST trial suggests
that cetuximab dose escalation gradually, even up to 500 mg/m2 weekly, could safely increase
response rates in patients who have no or a mild skin reaction within the first 3 weeks of
therapy [94]. However, cetuximab dose escalation according to grade of early skin reactions
is not a standard approach currently, since OS benefit could not be shown. Pruritus, another
common cutaneous adverse effect of anti-EGFR mAbs, is more common with panitumumab
(55% any grade) compared to cetuximab (18% any grade) [95].
5.2. Electrolyte disorders
Magnesium-wasting syndrome is observed in 22% of patients receiving anti-EGFR mAbs [90,
96] and consequent hypomagnesemia may be more prominent when oxaliplatin is used
concomitantly [97]. Hypokalemia is another important electrolyte disorder observed in
approximately 8% of patients receiving cetuximab [98]. Hypomagnesemia may lead to
secondary hypocalcemia and refractory hypokalemia. Thus, serum levels of magnesium,
potassium, and calcium should be monitored periodically during and for at least 8 weeks after
anti-EGFR containing therapy.
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5.3. Infusion reactions
Infusion reactions are more common with cetuximab (25%) compared with panitumumab
(4%), and more frequently observed in some areas of the middle southeastern United States
[91]. Most of the infusion reactions are severe and occur within 3 hours of the first infusion.
Cetuximab infusion should not exceed 5 mL/minute and premedication with an H1 receptor
antagonist is recommended. For patients who develop a severe reaction to cetuximab despite
premedication, desensitization or switching to panitumumab may be considered. Given the
lower rates of infusion reactions compared with cetuximab, routine premedication is not
recommended prior to panitumumab infusion.
5.4. Venous thromboembolism
Although not common, anti-EGFR mAbs may increase the risk of venous thromboembolism,
but not arterial thromboembolism, as shown in a meta-analysis [99].
6. Anti-EGFR mAbs for geriatric population
Approximately 70% of CRC cases develop over the age of 65 [100]. The efficacy and main
principles of mCRC treatment in the elderly are similar to younger patients. However, organ
function decline and comorbidities are more common in the elderly and make them more
vulnerable to side effects of systemic cancer therapies.
Because the number of older patients enrolled in clinical trials is small and these patients
usually have good performance status [101, 102], good quality evidence about safety and
efficacy of anti-cancer treatments in the elderly is limited. The majority of elderly patients are
neither fit nor frail, and there is no evidence to support or refute the benefit and safety of
therapy. Individualized treatment decision according to functional status, comorbidities,
toxicity profile of the drugs is essential in older patients.
Few data are available about the safety and efficacy of anti-EGFR mAbs in the elderly mCRC
patients. However, only older age should not be considered as an absolute contraindication to
use anti-EGFR mAbs in mCRC. A retrospective study including heavily pretreated KRAS WT
mCRC patients older than 70 years (n = 56) demonstrated that addition of cetuximab to
irinotecan was tolerable and beneficial in the elderly similar to younger patients [103]. Another
study analyzed 305 elderly and 352 younger (<65 years old) mCRC patients receiving chemo‐
therapy plus cetuximab. Efficacy and the prevalence of side effects was similar in older and
younger patients [104]. In contrast, a phase II trial of capecitabine plus cetuximab as first-line
treatment of mCRC demonstrated that rate of acneiform rash was higher in the elderly (n = 66)
[105].
Panitumumab monotherapy provides similar PFS benefit in the elderly compared with
younger patients and may be a well-tolerated first-line option for frail elderly patients with
WT RAS mCRC, as shown in a phase II study [12, 106]. A retrospective study demonstrated
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that toxicity-related dose reductions for panitumumab were required in about one-fourth of
frail elderly patients receiving first-line or second-line therapy for mCRC (n = 40) [107].
6.1. Anti-EGFR mAbs for patients with poor performance status
Regardless of age, individuals with a poor performance status (PS) (e.g., Eastern Cooperative
Oncology Group [ECOG] PS ≥2, Karnofsky PS <60) usually cannot tolerate chemotherapy and
have a poor prognosis [108]. However, particularly if PS decline is cancer related, patients with
mCRC who have a PS of 2 should be considered for chemotherapy. FU or capecitabine alone,
or cetuximab/panitumumab monotherapy (if RAS WT) are appropriate options for patients
who are not candidates for combination chemotherapy including oxaliplatin or irinotecan
because of their poor performance status.
6.2. Mechanisms of resistance to anti-EGFR treatment
Unfortunately, after a variable period of responsive phase, secondary resistance to anti-EGFR
mAbs develop. Therefore, it is a clear priority to understand the molecular and cellular basis
of primary and acquired resistance to cetuximab and panitumumab. The mutational status of
the EGFR signaling effectors (KRAS, BRAF, or PIK3CA) appears to be the main components
of resistance.
6.3. KRAS/NRAS/BRAF mutations
Prospective randomized studies showed that KRAS mutations are predictive of non-response
to anti-EGFR based treatment [8–12, 18–20]. However, KRAS mutation status is not enough to
select appropriate patients for anti-EGFR mAbs, because almost 60% of patients with KRAS
WT mCRC also have poor response to anti-EGFR mAbs [34]. Mutations in KRAS outside of
exon 2 and mutations in NRAS are also associated with lack of response to anti-EGFR mAbs
[38]. Thus, all patients with newly diagnosed mCRC should be tested for RAS mutation status,
as RAS mutation is the major cause of primary resistance to anti-EGFR mAbs.
BRAF oncogene encodes BRAF protein that is a member of RAS/RAF/MAPK pathway [109].
BRAF and KRAS mutations are mutually exclusive [110]. BRAF gene mutation (V600E) rate is
5–9% among patients with mCRC [111, 112]. Although BRAF mutation is a poor prognostic
factor for mCRC, as shown in the CRYSTAL and PETACC-3 studies [57, 113], the use of BRAF
as a predictive marker is unclear. BRAF mutation status does not predict the response to either
panitumumab or cetuximab in the first-line treatment of mCRC, as demonstrated in the
CRYSTAL and the PRIME studies [10, 57]. In contrast to the results in the first-line treatment,
BRAF mutation is a predictor of resistance to anti-EGFR treatment in the second-line therapy
or beyond [36, 50, 55].
Interestingly, vemurafenib, an orally administered BRAF V600 kinase inhibitor, has insuffi‐
cient activity when used alone in BRAF-mutated mCRC patients [114]. Vemurafenib resistance
in mCRC may be because of feedback activation of EGFR signaling [115, 116].
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6.4. Hyperactivation of PI3K-PTEN axis
Although 41% of mCRC patients do not have RAS or BRAF mutation, they do not respond to
anti-EGFR mAbs [55]. Oncogenic activation of the members of EGFR downstream pathways
other than RAS/RAF/MAPK (e.g., PI3K/PTEN pathway) might be responsible for the resistance
to anti-EGFR mAbs. It is well established that activating mutation in PI3KCA or inactivation
of PTEN phosphates can deregulate PI3K signaling pathway [117].
Mutation in PI3KCA and loss of PTEN are associated with resistance to anti-EGFR mAbs [118–
120]. BRAF negative, PTEN expressing, and PI3K non-expressing CRCs have higher response
rate and longer PFS and OS than others, suggesting that PI3K expression and PTEN loss might
be used as predictors of response to anti-EGFR mAbs in mCRC patients with WT KRAS [121].
The role of PI3K mutation on response to anti-EGFR mAbs in mCRC has been evaluated in a
number of studies [40, 58, 118, 122, 123]. Two of these studies demonstrated that PI3KCA
mutation and PTEN loss, which cause PI3K pathway activation, are significant predictors of
resistance to anti-EGFR mAbs [118, 122]. In contrast, PI3KCA mutation was not associated
with response to anti-EGFR mAbs in chemorefractory mCRC patients in another study [123].
PTEN inactivation is another predictor of resistance to anti-EGFR mAbs [118–120]. Moreover,
PI3K expression and PTEN loss are also associated with decreased survival in addition to poor
response to anti-EGFR mAbs [117].
Study Year Popula
tion
Patient
number
Regimen Median
PFS
(month)
p* Median
OS
(month)
p* Response rate (%) p*
Reidy
et al.128
2010 All 23 IMC-A12 (anti-IGF-1R
antibody)
5.9 – 5.2 – 0 –
21 IMC-A12 (anti-IGF-1R antibody) + 
Cetuximab
6.1 4.5 5
KRAS
WT
group
20 IMC-A12 (anti-IGF-1R antibody) + 
Cetuximab
9.4 10.9 0
*95% confidence interval.
PFS, progression-free survival; OS, overall survival; All, all patients group; WT, wild type; MT, mutant type; N/A: not
available; KRAS, KRAS exon 2, codons 12 and 13; anti-IGF-1R, insulin-like growth factor-1 receptor inhibitor.
Table 3. Selected phase II study of an insulin-like growth factor-1 receptor inhibitor for metastatic colorectal cancer
refractory to cetuximab or panitumumab
6.5. Hyperexpression or hyperactivation of type 1 insulin-like growth factor receptor
(IGF-1R)
The type 1 insulin-like growth factor receptor (IGF-1R) is a tyrosine kinase receptor that
functions by activating downstream signaling pathways, including MAPK and PI3K/AKT.
IGF-1R overexpression, which may cause neoplastic transformation of cultured cells, is present
Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer
http://dx.doi.org/10.5772/62304
359
in several types of human tumors [124, 125], and its downregulation can inhibit the growth of
tumor cells [126]. These findings make IGF-1R an attractive candidate as an anti-cancer
therapeutic target. A previous study showed that combination therapy of mAbs targeting
IGF-1R and EGFR results in further inhibition of CRC cell-line growth [127]. A phase II study
evaluated the safety and the efficacy of human anti-IGF-1R mAb (either alone or in combina‐
tion with cetuximab) in mCRC patients, and both treatment modalities were reported as
insufficient in chemorefractory mCRC patients [128] [Table 3].
6.6. EGFR-tyrosine kinase inhibitors in mCRC
The orally active EGFR-tyrosine kinase inhibitors erlotinib and gefitinib prevent downstream
signaling of the receptor and are inactive as monotherapy of mCRC [129, 130]. Promising
results have been reported in phase II trials of erlotinib with capecitabine and oxaliplatin [131]
and gefitinib plus FOLFOX in mCRC patients [132, 133]. However, randomized trials are
required to evaluate the benefits of gefitinib or erlotinib in combination with chemotherapy
by comparing chemotherapy alone.
7. Future perspectives
The mAbs targeting EGFR (cetuximab and panitumumab) have shown remarkable efficacy in
the treatment of mCRCs. Despite the significance of KRAS mutations, the efficacy of anti-EGFR
monoclonal antibodies in the 60–70% of mCRC patients with KRAS WT tumors is still limited,
with response rates between 10 and 40% [134]. Similar to other targeted therapies, anti-EGFR
drugs are active only in a fraction of patients and most of them subsequently become resistant
to the treatment. Accordingly, two major challenges need to be addressed to optimize the
efficacy of anti-EGFR therapies. The first is to identify the genetic alterations associated with
the clinical response to anti-EGFR mAbs. The second is the elucidation of the molecular basis
for primary or acquired resistance to these drugs. It seems likely that a comprehensive
biomarker analysis will be required to identify the mCRC patients who will truly benefit from
anti-EGFR mAbs.
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